Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effect of Evolocumab on Heart Disease in Patients Needing Coronary Angiography

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment on patients with atherosclerotic cardiovascular disease, a condition where the blood vessels become narrowed or blocked due to the buildup of fatty deposits. The treatment being tested is a medication called Repatha, which contains the active substance evolocumab. This medication is administered as a solution for injection using a pre-filled pen.

The purpose of the study is to examine how Repatha affects a specific heart condition known as coronary microvascular dysfunction, which involves problems with the small blood vessels in the heart. The study will compare the effects of a single dose of Repatha with no treatment in patients who have been diagnosed with atherosclerotic cardiovascular disease and require a procedure called coronarography, which is an imaging test to look at the heart's blood vessels.

Participants in the study will receive either the medication or no treatment and will be monitored over a period of four weeks. The study aims to provide insights into how Repatha might help improve the function of the heart's small blood vessels in patients with this type of heart disease. The results could potentially lead to better treatment options for individuals with atherosclerotic cardiovascular disease.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on criteria such as age, weight, LDL-C level, and the need for coronarography.

    Informed consent is required to participate in the study.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to evaluate the current state of coronary microvascular function using noninvasive imaging tests.

    This assessment helps establish a baseline for comparison after treatment.

  3. Step 3

    Treatment administration

    A single administration of evolocumab is given as a subcutaneous injection.

    The medication used is Repatha 140 mg solution for injection in pre-filled pen.

  4. Step 4

    Monitoring period

    A monitoring period of 4 weeks follows the administration of the medication.

    During this time, no additional treatment is provided, allowing for observation of the medication's effects.

  5. Step 5

    Follow-up assessment

    After 4 weeks, a follow-up assessment is conducted to measure the index of microcirculatory resistance (IMR) during invasive coronary angiography.

    Additional parameters such as troponin I levels, coronary angiography parameters, and resting ultrasound parameters are also evaluated.

  6. Step 6

    Completion of study participation

    Upon completion of the follow-up assessment, participation in the study concludes.

    Results from the assessments are used to compare the effects of the treatment on coronary microvascular dysfunction.

Who can join the trial?

6 criteria

  • Male or female patient, aged between 40 and 85 years old.
  • Weighs more than 50 kilograms.
  • Has an LDL-C level of at least 0.7 grams per liter. LDL-C is a type of cholesterol in the blood, and this level should be from a test done in the last 6 months.
  • Needs a procedure called coronarography, which is a special X-ray test to see the heart's blood vessels, as recommended by European guidelines.
  • Is affiliated with social security, meaning they have access to a government health insurance program.
  • Has signed an informed consent form, which means they agree to participate in the study after understanding all the details.

Who cannot join the trial?

9 criteria

  • Patients who have any other serious health conditions that could interfere with the study.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had a recent heart attack or stroke.
  • Patients who have severe liver or kidney disease.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a known allergy to the study medication.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who are unable to follow the study procedures or attend study visits.
  • Patients who have any condition that the study doctors believe would make it unsafe for them to participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Evolocumab is a medication used in this clinical trial to study its effect on coronary microvascular dysfunction in patients with atherosclerotic cardiovascular disease. It is a type of drug known as a PCSK9 inhibitor, which helps to lower cholesterol levels in the blood. The trial aims to see how a single administration of evolocumab affects the small blood vessels in the heart over a period of four weeks.

What is already known about the treatment

Evolocumab – Evolocumab is administered as an injection under the skin, typically in the form of a pre-filled syringe or auto-injector. It is currently used in medicine to help manage cholesterol levels, particularly in patients with atherosclerotic cardiovascular disease. The main therapeutic indication for evolocumab is to lower LDL cholesterol levels in the blood, which can help reduce the risk of heart disease. At the molecular level, evolocumab works by inhibiting a protein called PCSK9, which leads to increased removal of LDL cholesterol from the bloodstream. It is classified as a PCSK9 inhibitor in pharmacology.

Investigated diseases

Atherosclerotic Cardiovascular Disease – This disease involves the buildup of fatty deposits, known as plaques, within the walls of arteries, leading to their narrowing and hardening. Over time, this can restrict blood flow to various organs and tissues, potentially causing symptoms like chest pain or shortness of breath. The progression of the disease can lead to more severe complications, such as heart attacks or strokes, if the blood supply becomes significantly reduced or blocked. The condition often develops slowly over many years and may not present noticeable symptoms until the arteries are significantly affected. Factors such as high cholesterol, high blood pressure, smoking, and diabetes can contribute to the development and progression of atherosclerosis. Regular monitoring and lifestyle changes are crucial in managing the disease's progression.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-519012-14-00Protocol code38RC19.186Estimated enrolment66 patientsSponsorCentre Hospitalier Universitaire Grenoble Alpes

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).